Evidence map›Paper›PMID 39493231›Full record

ReviewMetabolism open2024

Receptor tyrosine kinases and steroid hormone receptors in breast cancer:

Awgichew Behaile Teklemariam, Zelalem Tilahun Muche, Melaku Mekonnen Agidew, Anemut Tilahun Mulu, Edgeit Abebe Zewde, Nega Dagnew Baye, Dagnew Getnet Adugna, Lemlemu Maru, Teklie Mengie Ayele

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Metabolism open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Awgichew Behaile TeklemariamDepartment of Medical Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Zelalem Tilahun MucheDepartment of Medical Physiology, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Melaku Mekonnen AgidewDepartment of Medical Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Anemut Tilahun MuluDepartment of Medical Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Edgeit Abebe ZewdeDepartment of Medical Physiology, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Nega Dagnew BayeDepartment of Human Anatomy, School of Medicine, College of Health Sciences, University of Gondar, Gondar, Ethiopia.
Dagnew Getnet AdugnaDepartment of Human Anatomy, School of Medicine, College of Health Sciences, University of Gondar, Gondar, Ethiopia.
Lemlemu MaruDepartment of Medical Physiology, School of Medicine, College of Health Sciences, University of Gondar, Gondar, Ethiopia.
Teklie Mengie AyeleDepartment of Pharmacy, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer development and progression are driven by intricate networks involving receptor tyrosine kinases (RTKs) and steroid hormone receptors specifically estrogen receptor (ER) and progesterone receptor (PR). This review examined roles of each receptor under normal physiology and in breast cancer, and explored their multifaceted interactions via signaling pathways, focusing on their contributions to breast cancer progression. Since defining the mechanism by which these two-receptor mediated signaling pathways cooperate is essential for understanding breast cancer progression, we discussed the mechanisms of cross-talk between RTKs and ER and PR and their potential therapeutic implications as well. The crosstalk between RTKs and steroid hormone receptors (ER and PR) in breast cancer can influence the disease's progression and treatment outcomes. Therefore, understanding the functions of the aforementioned receptors and their interactions is crucial for developing effective therapies.

Indexed as

Breast cancerCross-talkERPRRTKs

Identifiers

PMID39493231
PMCPMC11530601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.